Antidiarrhoeals (A61P1/12)

A   Human necessities(312810)
A61P1/12                     Antidiarrhoeals(39)
Racecadotril liquid compositions // 2643325
FIELD: medicine.SUBSTANCE: group of inventions refers to medicine, namely to liquid composition for treatment of diarrhea, dosage form for treatment of diarrhea and method of treating a subject suffering from diarrhea. Liquid composition for treatment of diarrhea contains racecadotril and a sulfobutyl ether derivative of β-cyclodextrin, where the products of chemical degradation of racecadotril in the liquid composition are less than about 10 % after 3 months of storage at 40 °C.EFFECT: invention allows to obtain a stable liquid composition.19 cl, 2 ex, 12 tbl
Lipid compositions of racecadotril // 2632441
FIELD: pharmacology.SUBSTANCE: composition includes racecadotril, polyoxyl 35 castor oil as a surfactant, caprylic/capric acid triglycerides 70:30 as lipid and water. A dosage form for diarrhea treatment comprising the said pharmaceutical microemulsion composition and a method of treatment of a subject suffering from diarrhea comprising oral administration of said composition are also described. The liquid pharmaceutical microemulsion composition of racecadotrile as per invention is stable for 3 months at 40°C.EFFECT: increased stability.6 cl, 5 tbl, 2 ex
Preparation for treatment of gastrointestinal diseases of calves protecting with diarrhea signs // 2629814
FIELD: veterinary medicine.SUBSTANCE: claimed preparation contains glucose, sodium chloride, potassium chloride, calcium lactate, levomycetin and phthalazole and further contains phytazine and inulin vegetable at the following ratio of the constituent components, g/l of the aqueous solution: inulin vegetable - 9.0, phytazine - 0.75, levomycetin - 1.0, phthalazole - 1.0, glucose - 30.0, sodium chloride - 9.0, potassium chloride - 0.2, calcium lactic acid - 1.0.EFFECT: highly effective for the treatment and prevention of gastrointestinal diseases of calves.1 tbl, 1 ex

Content for stimulating metabolic processes, immune system, prevention the diseases and diarrhea // 2620554
FIELD: veterinary medicine.SUBSTANCE: declared composition has metabolic, immunomodulating and antimicrobial activity for preventing gastrointestinal diseases with diarrhea syndrome, comprising succinic acid and SDA iodinol second fraction with the following ratio of components per 1000 ml of aqueous solution: Succinic Acid - 10.0 g iodinol - 250 ml of SDA second fraction - 40 ml. The following is also claimed: composition having metabolic, immunomodulating and antimicrobial activity for preventing gastrointestinal diseases diarrhea syndrome comprising succinic acid, iodinol, levamisole with the following ratio of components per 1000 ml of aqueous solution: Succinic Acid - 10.0 g iodinol - 250 ml , levamisole - 10.0 g.EFFECT: stimulation of metabolism and the immune system, prevention of gastrointestinal diseases, and increase the activity of the growth of young farm animals.2 cl, 6 tbl, 3 ex
ethod for prevention and treatment of newborns calves diarrheal diseases // 2619859
FIELD: veterinary medicine.SUBSTANCE: method comprises oral applying of the complex with metabolic agents, immunomodulating and anti-infective effect of 100 ml 30 minutes prior to the drinking colostrum or milk twice a day for 5 days. The cure comprises succinic acid as metabolite, immunopotentiator - antiseptic-stimulator of Dorogov of second fraction (ASD-2) or levamisole, the antimicrobial component - iodinol in the following ratio: succinic acid - 1 g; antiseptic stimulator of Dorogov of second fraction (ASD-2) - 4 ml or levamisole - 0.05 g; iodinol - 30 ml; Boiled water - 100 ml.EFFECT: cure is highly effective for the prevention and treatment of diarrhea of newborn calves.7 tbl, ex 5
Pharmaceutical combination comprising ibat-inhibitor and bile acid binder // 2619215
FIELD: pharmacology.SUBSTANCE: group of inventions can be used for the application of the IBAT inhibitor and the bile acid binder (cholestyramine, colestipol, or colesevelam) for preparing the combination for simultaneous, sequential or separate introduction in the treatment of the liver diseases. Herewith the bile acid binder is located in the core and is composed for release in the colon, and the IBAT-inhibitor is located in the outer layer, composed for immediate or delayed release in the distal jejunum or in the proximal ileum. Also the use of the pharmaceutical composition is provided, comprising an IBAT-inhibitor and a bile acid binder for preparing the medicine for the treatment of the liver diseases.EFFECT: group of inventions provides treatment of the liver diseases.14 cl, 2 tbl, 20 ex
edication for treating calves in case of acute intestinal diseases // 2611342
FIELD: medicine.SUBSTANCE: invention relates to field of veterinary and is intended for treatment of calves in case of diarrhoea of infectious and alimentary-functional nature. Medication contains sodium chloride, hydrocarbonate, sodium chloride, glucose, iodine-bismuth complexonate (IBC) with the following component ratio, g/l of solution: sodium chloride - 3.5; sodium hydrocarbonate - 2.5; potassium chloride - 1.5; glucose - 20.0; IBC - 0.5.EFFECT: application of the invention ensures increase of effectiveness and safety of treatment in case of acute intestinal diseases of calves.2 dwg, 5 tbl, 2 ex

"stomstab" preparation for treating gastrointestinal diseases in calves // 2602455
FIELD: veterinary science.SUBSTANCE: invention refers to veterinary science and aims at treating gastrointestinal diseases in calves. Calves with gastrointestinal diseases were fed a formulation containing zeolite, loperamide, sodium acetate, bergenia root extract and shrubby cinquefoil. Dose of 2 times a day in a dose of 0.1 g per head per 1 kg of calf body weight.EFFECT: method allows to quickly restore disorders of gastrointestinal tract, increased hemoglobin, erythrocytes, leukocytes in blood of animals and increase level of bactericidal and lysozyme activity of serum.1 cl, 3 tbl, 2 ex

ethods and compositions for treating hiv-associated diarrhoea // 2597746
FIELD: medicine.SUBSTANCE: present group of inventions relates to virology and gastroenterology, and concerns treating HIV-associated diarrhoea. Crofelemer is administered in a daily dose of 250-1,000 mg.EFFECT: this provides effective treatment of diarrhoea in given group of patients, as well as reduced side effects due to use preparation in low doses.27 cl, 23 tbl, 3 dwg, 10 ex

Food composition with probiotics // 2595396
FIELD: food industry.SUBSTANCE: disclosed is use of baby food for production of a nutritional composition for baby feeding. Baby food contains from 5 to 16 en% protein, from 30 to 60 en% fat, from 25 to 75 en% carbohydrates, as well as Bifidobacterium breve and Lactobacillus paracasei.EFFECT: invention provides higher level of Bifidobacteria and Lactobacilli in feces in infants and control of their population in intestine at level of types to values close to values observed in breastfed children.13 cl, 1 dwg, 4 tbl, 10 ex

Diaminopyrimidine derivatives and methods for production thereof // 2587981
FIELD: pharmaceutics.SUBSTANCE: present invention relates to a novel compound of diaminopirimidine formula 1 or its pharmaceutically acceptable salts possessing the properties of 5-HT4 receptors agonist. In formula 1 (Formula 1)R1 denotes a phenyl group substituted with one or more substitutes selected from a group consisting of hydroxy, amino, halogen, cyano, nitro, C1-2alkyl (where C1-2alkyl optionally substituted with halogen), C1-5alkoxy,C1-5alkylthio, C1-5alkoxycarbonyl and aminokarbonil, or heteroaryl group selected from a group consisting of furanyl, pyrrolyl, tiofenil, hinolinil, hromenonil, indolil, benzimidazole-4-yl, benzimidazole-5-yl, benzimidazole-6-yl, benzimidazole-7-yl and indazolil, herewith the heteroaryl group can be optionally substituted with one or more substitutes selected from a group consisting of C1-5alkyl (where C1-5alkyl optionally substituted with halogen) and C1-5alkoxy, R2 denotes a nitrogen-containing cyclic group selected from a group consisting of the following formulae from A to D (where * symbol in A-D formulae denotes the position of this group attachment to a compound of formula (1))R3 denotes C1-5alkyl group, optionally substituted by phenyl, R4 denotes hydrogen, C1-5alkyl group optionally substituted with a substitute selected from a group consisting of hydroxy, C1-5alkylamino, pyrrolidinyl and hydroxy-C-1-5alkylamino; C1-5alkoxycarbonyl group or amin-carbonyl group, R5 denotes hydrogen, hydroxyl group; C1-5alkoxy group; C1-5alkyl group, optionally substituted with a substitute selected from a group consisting of amino and C1-5alkoksikarbonilamino; or group selected from a group consisting of the following formulae of E to I (where * symbol in E-I formulae is the position of this group attachment to one of the of A-D formula compounds),R6 means hydrogen, hydroxyl group or C1-5alkyl group optionally substituted with hydroxy, X denotes -CH(R7)-, -C(=O)-, -N(R8)- or -O-, R7 means hydrogen; hydroxyl group; amino-carbonyl group; phenyl group or C1-5alkyl group optionally substituted with hydroxy, R4 and R5, R5 and R6, R4 and R6 or R5 and R7 may be interconnected while forming 5- or 6-element ring; the said ring may be carbocyclic or additionally contain an oxygen atom as a heteroatom, R8 denotes hydrogen or C1-5alkyl group. Values of R9-R12 radicals are given in the patent claim.EFFECT: invention relates to the use of formula 1 or its pharmaceutically acceptable salt for preparing a drug in order to prevent or treat gastrointestinal motility dysfunction; Gastrointestinal motor dysfunction is gastroesophageal reflux disease (GERD), a lock (constipation), an irritable bowel syndrome (IBS), dyspepsia, postoperative intestinal obstruction, prolonged gastric emptying, gastroparesis, intestinal pseudo-obstruction, content transit deceleration over the colon induced by medicines or diabetic gastroparesis.8 cl, 38 tbl, 355 ex

Diaminopyrimidine derivatives and methods for production thereof // 2587493
FIELD: pharmaceutics.SUBSTANCE: present invention relates to a novel diaminopyrimidine derivative formula 1 or pharmaceutically acceptable salts thereof possessing properties of agonist of 5-HT4 receptors. In formula 1 (Formula 1)R1 denotes a phenyl group substituted with one or more substitutes selected from a group consisting of hydroxy, amino, halogen, cyano, nitro, C1-5alkyl (where C1-5alkyl is optionally substituted with halogen), C1-5alkoxy, C1-5alkylthio, C1-5alkoxycarbonyl, aminosulphonyl and benzyloxycarbonylamino; or heteroaryl group selected from a group comprising pyridinyl, quinolinyl, chromenonyl, indolyl, indolinyl and benzimidazolyl, wherein heteroaryl group can be optionally substituted with one or more substitutes selected from a group consisting of C1-5alkyl (where C1-5alkyl is optionally substituted with halogen) and acetyl, R2 denotes hydrogen; C1-5alkyl group, optionally substituted with a substitute selected from a group consisting of hydroxy, C1-5alkoxy, benzylamino (where benzylamino is optionally substituted by halogen), phenylamino, C1-5alkylamino, C3-6cycloalkylamino and hydroxy-C1-5alkylamino; C1-5alkoxycarbonyl group or formyl group, R3 denotes hydrogen, hydroxyl group; C1-5alkyl group, optionally substituted with a substitute selected from a group consisting of C1-5alkoxycarbonylamino and di-C1-5alkylamino, or group selected from a group consisting of following formulae A, B, D and E (where symbol * in formulae A, B, D and E denotes position of attachment of said group of compounds of formula 1),R4 denotes hydrogen, R5 denotes C1-5alkyl group, optionally substituted phenyl or C2-6alkenyl group, optionally substituted phenyl or C3-6cycloalkyl, R6 denotes C1-10alkyl group, optionally substituted with a substitute selected from a group consisting of hydroxy, halogen, C1-5alkoxy, amino, C1-5alkoxycarbonylamino, benzyloxycarbonylamino, di-C1-5alkylamino, C1-5alkoxy-C1-5alkyloxy, phenoxy, benzyloxy, phenyl (where phenyl is optionally substituted with one or more substitutes selected from a group consisting of halogen, amino and C1-5alkoxy), thiophenyl, pyridinyl, piperidinyl, piperazinyl (where piperazinyl is optionally substituted with benzyl) and acetyl; C3-6cycloalkyl group; piperidinyl group; C1-10alkenyl group, optionally substituted phenyl; trifluoromethyl group, trifluoroethyl group or a phenyl group optionally substituted with halogen, R7 denotes hydrogen, R8 and R9 each independently denote hydrogen; C1-10alkyl group, optionally substituted with substitute selected from a group consisting of amino, C1-5alkoxycarbonylamino, hydroxy, C1-5alkylthio, C3-10cycloalkyl, phenyl (where phenyl is optionally substituted with one or more substitutes selected from a group consisting of hydroxy, C1-5alkyl, mono-or di-C1-5alkylamino, trifluoromethyl, halogen, C1-5alkoxy C1-5alkylcarbonyloxy), thiophenyl, pyrrolyl, furanyl (where furanyl is optionally substituted with mono-or di-C1-5alkyl), pyridinyl and benzyloxy; piperidinyl group, optionally substituted benzyl, benzoyl, C1-5alkyl or C1-5alkylcarbonyl; azetidinyl group, optionally substituted C1-5alkoxycarbonyl; C1-5alkylsulphonyl group or C3-10cycloalkyl group.EFFECT: invention relates to use of formula 1 or its pharmaceutically acceptable salt for preparing a drug for preventing or treating gastrointestinal motility dysfunction; gastrointestinal motor dysfunction is gastroesophageal reflux disease (GERD), lock (constipation), irritable bowel syndrome (IBS), dyspepsia, postoperative intestinal obstruction, prolonged gastric emptying, gastroparesis, intestinal pseudo-obstruction,drug-induced delayed transit content over colon or diabetic gastroparesis.9 cl, 54 tbl, 495 ex

Preparation for prevention and treatment of diarrhoea in calves // 2583555
FIELD: veterinary science.SUBSTANCE: invention can be used for prevention and treatment of diarrhoea in calves. That is ensured by preparation containing hyperimmune polyvalent blood serum against diarrhoea with antibody titre of 1:300-1:600 in effective amount of sodium hypochlorite solution concentrated 300-350 mg/l at ratio of ingredients, wt%: serum: sodium hypochlorite 70:30-60:40, preserving agent, wherein preserving agent used is sodium hypochlorite solution in concentration of 700-750 mg/l in amount of 10-11 % of preparation.EFFECT: invention reduces cost of preparation and improves environmental safety of use while maintaining high efficiency and absence of side effects.1 cl, 4 tbl

4-substituted-2-phenoxyphenylamine modulators of delta-opioid receptors // 2553453
FIELD: medicine, pharmaceutics.SUBSTANCE: invention relates to novel compounds of formula I, possessing ability of binding with delta-opioid receptors. In formula R1 is selected from the group, consisting of i) phenyl, optionally substituted with one-two substituents, independently selected from the group, consisting of C1-4alkyl, C1-4alcoxy, C1-4alkylthio, hydroxyl, di(C1-4alkyl), aminocarbonyl, chlorine and fluorine, in such a way that only one di(C1-4alkyl)aminocarbonyl is present; ii) naphthyl; iii) pyridinyl, optionally substituted with one substituent, selected from the group, consisting of C1-4alkyl, C1-4alcoxy, C1-4alkylthio, hydroxy, fluorine, chlorine and cyano; iv) pyrimidin-5-yl; v) furanyl; vi) thienyl; vii) 5-oxo-4,5-dihydro-[1,2,4]oxodiazol-3-yl; and viii) di(C1-2alkyl)aminocarbonyl; Y represents ethyl, vinyl or bond; or Y represents O, when R1 represents optionally substituted phenyl, where substituent represents C1-4alcoxy; R2 represents phenyl, optionally substituted with one-two substituents, independently selected from the group, consisting of C1-4alkyl, C1-4alcoxy, fluorine, chlorine and cyano, trifluoromethoxy and hydroxy; or R2 represents phenyl, substituted with one aminocarbonyl, di(C1-4alkyl)aminocarbonyl, C1-4alcoxycarbonyl or carboxysubstituent; R3 is selected from the group, consisting of i) 3-aminocyclohexyl; ii) 4-aminocyclohexyl; iii) piperidin-3-yl; iv) piperidin-4-yl; v) pyrrolodin-2-yl-methyl, in which pyrrolodin-2-yl is optionally substituted by 3-rd or 4-th position with one or two fluorine-substituents; vi) azetidin-3-yl; vii) 2-(N-methylamino)ethyl; viii) 3-hydroxy-2-aminopropyl; ix) piperidin-3-yl-methyl; x) 1-azabicyclo[2.2.2]octan-3-yl; and xi) 8-azabicyclo[3.2.1]octan-3-yl; or R3 together with Ra and nitrogen atom, which they both are bound to, form piperazinyl, optionally substituted with 4-C1-4alkyl; Ra represents hydrogen, 2-(N-methylamino)ethyl or C1-2alkyl, optionally substituted with azetidin-3-yl.EFFECT: compounds can be used in treatment of pain in the range from medium to strong, caused by diseases or conditions, such as osteoarthritis, migraine, burn, fibromyalgia, cystitis, rhenite, neuropathic pain, idiopathic neuralgia, toothache, etc.21 cl, 4 tbl, 26 ex
Agent for prevention of gastrointestinal diseases in calves with diarrhea syndrome // 2538619
FIELD: veterinary medicine.SUBSTANCE: agent for prevention of gastrointestinal diseases in calves with diarrhea syndrome comprises wt % silver nitrate 0.01-0.5, levamisole base 3.0-8.0, ascorbic acid 1.0-12.0 and water for injection - the rest.EFFECT: antibacterial, immunomodulatory effect, anti-stress, antioxidant effect, and increase in effectiveness of prevention of gastrointestinal diseases in calves with diarrhea syndrome.10 tbl, 6 ex

ethod of correction of immune deficiency and prevention of gastrointestinal diseases of new-born calves // 2535014
FIELD: veterinary medicine.SUBSTANCE: method comprises giving to calves to drink the tincture of the combination herbal medicinal product - the grass of St. John's wort, meadowsweet, common yarrow, common nettle, rhizome of leather bergenia, root and rhizome of marsh cinquefoil, Scotch pine needles. At that the tincture fermented with microorganisms "EM Kurung" is used. The tincture is prepared by mixing 200 ml the tincture of the combination herbal medicinal product with 40 ml of the finished product "EM Kurung" and maintaining at the temperature of 18-20°C during the day, followed by filtration. EM-preparation "Baikal EM 1" is given to dry cows for 30 days prior to calving as a single dose in a dose of 30 ml/head. Mixoferon, sedimin and nitamin are additionally prescribed to new-born calves according to the following schedule: from the second feeding the tincture of the combination herbal medicinal product is watered with colostrum, fermented with microorganisms of EM-preparation "EM Kurung" at a dose of 150 ml/head dualfold for 10 days. On the 1, 2 and 8 day of life, mixoferon is injected intramuscularly at a dose of 9 ml/head. On the 1 and 8 day of life - nitamin and sedimin at a dose of 4 ml/head.EFFECT: use of the claimed method enables to increase the immunobiological reactivity, energy of growth, provides prevention of gastrointestinal diseases of new-born calves.4 tbl, 3 ex

Product for storage of lyophilised lactic acid bacteria mixed with powder for solution for oral rehydration // 2527515
FIELD: packaging industry.SUBSTANCE: present invention relates to packaging products sensitive to moisture. The probiotic product comprises lyophilised lactic acid bacteria mixed with anhydrous powder for solution for oral rehydration. At that the lyophilised lactic acid bacteria and the anhydrous powder for solution for oral rehydration are packaged in foil with a desiccant integrated into the foil. Also the method of long-term storage of viable lyophilised probiotic lactic acid bacteria is provided. The method comprises providing the anhydrous powder for solution for oral rehydration; mixing lyophilised lactic acid bacteria with anhydrous powder for solution for oral rehydration; packing the mixed lyophilised lactic acid bacteria and the anhydrous powder for solution for oral rehydration in the package comprising the chemical desiccant material inserted into a layer of foil; and sealing the package.EFFECT: invention enables to extend the shelf life of the probiotic product.13 cl, 1 dwg, 1 tbl, 4 ex

Fatty acid derivatives for oral administration providing improved taste qualities // 2520070
FIELD: chemistry.SUBSTANCE: invention relates to novel derivatives of short-chain fatty acids, in particular derivatives of butyric acid, having physicochemical characteristics suitable for an easy oral administration, being devoid of the unpleasant organoleptic properties that characterise butyrate.EFFECT: novel compounds have an easily weighable form, are stable to acids and alkalis and are capable of releasing the acid in the small and large intestines continuously over a long time.7 cl, 5 dwg, 15 ex

Pharmaceutical composition for reduction of primary radiation response and early transient incapability // 2509557
FIELD: medicine, pharmaceutics.SUBSTANCE: pharmaceutical composition for the reduction of a primary radiation response and an early transient incapacity containing ondansetron and gastrozepin in mass ratio 1-12:2-15; the composition is used as an injectable dosage form.EFFECT: what is developed is the new composition.3 cl, 3 tbl, 2 dwg
Diarrhoea risk reduction // 2491080
FIELD: medicine, pharmaceutics.SUBSTANCE: invention refers to pharmaceutical industry, particularly to using probiotics in the manufacture of a drug or a therapeutic nutritional composition for long-term prevention of diarrhea in infants. Using the probiotic Lactobacillus rhamnosus ATCC 53103 or Lactobacillus rhamnosus CGMCC 1.3724, and the probiotic Bifidobacterium longum ATCC BAA-999 in the manufacture of a drug or a therapeutic nutritional composition to be introduced into an infant for at least three months for the purpose of long-term prevention of diarrhoea, wherein the probiotic is introduced into a breastfeeding infant from a nursing mother.EFFECT: using the above probiotic strains from the nursing mother is effective for the purpose of long-term prevention of diarrhoea in infants.6 cl, 2 ex
Composition for treating viral diseases in animals // 2482871
FIELD: medicine.SUBSTANCE: invention refers to veterinary science, and aims at treating viral diseases in animals. What is declared is a composition for treating viral diseases in animals, containing two subtypes of vertebrate recombinant interferon mixed in equal molar proportions.EFFECT: use of the declared composition enables ensuring the substantial increase of the therapeutic effect of recombinant interferons and minimising the potential adverse effects associated with their use.4 ex

Probiotic in pre- and/or postoperative period // 2470652
FIELD: medicine.SUBSTANCE: what is presented is the use of the strain Lactobacillus johnsonii in preparing a probiotic composition for prevention of postoperative abdominal and pelvic infections caused by pelvic liquid accumulation, anastomosis leakage, or caused by bacterial translocation.EFFECT: colonic L Johnsonii Lai colonisation in the patients underwent colectomy for colorectal adenocarcinoma.11 cl, 1 dwg, 1 tbl, 2 ex
ethod of stimulating intestinal barrier integrity after nonvaginal delivery // 2437581
FIELD: medicine.SUBSTANCE: invention relates to feeding of newborn babies delivered by Caesarian section. Claimed is change of composition which contains long-chain polyunsaturated fatty acid and, at least, one substance, selected from group, consisting of (a) nucleotide and (b) nucleotide precursor, selected from group consisting of nucleotides, purine bases, pyridine bases, ribose and deoxyribose for obtaining composition for introduction to newborn baby delivered by Caesarian section, for treatment and/or prevention of infection, diarrhea, intestine phlegmon, allergy, atopic eczema, asthma, allergic rhinitis and/or allergic conjunctivitis. Composition can also be used to improve intestinal maturation, reduction of intestinal permeability and/or for treatment of disorders associated with intestinal barrier, in newborn baby delivered by Caesarian section. Introduced to newborn baby composition is not human breast milk.EFFECT: invention makes it possible to improve intestinal flora of newborn babies, delivered by Caesarian section.12 cl, 5 tbl, 6 ex
Composition for treatment and/or prevention of allergy, asthma, infection and atopic dermatitis with children born by cesarean section (versions) // 2424736
FIELD: food industry.SUBSTANCE: invention relates to food industry and deals with alimentation of children born by cesarean section. One proposes application of a composition including indigestible oligosaccharides to produce a composition for treatment and/or prevention of diseases with children born by cesarean section. The disease is selected from the group including asthma, allergy, infection and atopic dermatitis. Indigestible oligosaccharides content in the composition is 0.5 - 75 g per 100 g of dry weight of the composition. Alternatively the composition may include at least 5 wt % of indigestible oligosaccharides, at least 1 wt % of oligosaccharide consisting of uronic acid remains in terms of dry weight of the composition while total weight of indigestible oligosaccharides is 0.1 - 10 g per portion. Alternatively the composition may content 5-100 mg of nucleotides per 100 g of dry weight of the composition. Alternatively the composition may include 102 - 1013 CFU of bacteria per 1 g of dry weight of the composition.EFFECT: invention allows to improve intestine maturation, enhance intestinal barrier and so to improve systemic condition of children born by caesarean section as well as promotes prevention and/or treatment of infection and other diseases with children born by caesarean section.18 cl, 3 tbl, 5 ex

Prodrug of adenosine a2b receptor antagonists // 2415858
FIELD: chemistry.SUBSTANCE: invention relates to compounds of formula in which R1 and R2 independently denote C1-6alkyl; R4 denotes phenyl, substituted with trifluoromethyl if necessary; X denotes hydrogen or methyl; and Y denotes -C(O)R, where R denotes C1-6alkyl; or Y denotes -P(O)(OR5)2, where R5 denotes hydrogen or C1-6alkyl; or pharmaceutically acceptable salts thereof. Said compounds are prodrugs of adenosine A2B receptor. The invention also relates to a pharmaceutical composition which is an adenosine A2B receptor antagonist based on the compound of formula I.EFFECT: formula I compounds and the pharmaceutical composition can be used in treating different diseases in mammals, such as gastrointestinal disorders, immunological disorders, allergic disorders, neurological disorders, cardiovascular disorders and diseases associated with cell hyperproliferation.13 cl, 1 tbl, 15 ex
ethods of changing stool quality and/or frequency // 2390342
FIELD: medicine, veterinary science.SUBSTANCE: group of inventions concerns veterinary. A method for improving stool quality in animals consists in regulating the balance of metabolised cations and metabolised anions consumed by an animal in good supply for improving stool quality. A method of changing stool frequency in the animal includes regulating the balance of metabolised cations and metabolised anions consumed by the animal in good supply for changing stool frequency. The composition for changing stool quality and/or frequency in animals contains at least one component chosen from the group including metabolised cations, and at least one component chosen from the group including metabolised anions where the balance of metabolised cations and metabolised anions is regulated by an amount changing stool quality and/or frequency in animals.EFFECT: group of inventions allows maintaining normal functioning of intestines in animals.22 cl, 1 tbl, 1 ex
Preparation "diaron" for treatment of acute gastrointestinal diseases of newborn calves // 2381796
FIELD: veterinary.SUBSTANCE: preparation of treatment of gastrointestinal diseases in newborn calves, includes zeolite, tetracycline, sodium acetate and flour of dried leather bergenia rhizome (Bergenia crassifolia), at the following ratio of components, wt %: Zeolite 44.5-48.5; Sodium acetate 44.5-48.5; Flour from dried rhizome of leather bergenia (Bergenia crassifolia) 4.2-8.2; Tetracycline 1.0-2.0. Preparation is fed in dose of 35 g per head 2 times per day until recovery.EFFECT: therapeutic efficiency makes 100%.1 tbl, 4 ex
Diarrheal syndrome treatment in sucking pigs // 2358752
FIELD: medicine; veterinary science.SUBSTANCE: cerebrolysin dosed 1 ml once a day within 3-4 days is injected intramuscularly to an affected animal.EFFECT: high effectiveness.1 tbl
edication for treatment of irritate bowels syndrome with diarrhea prevalence // 2351327
FIELD: medicine.SUBSTANCE: invention relates to medicine and represents pharmacologic composition for diarrhea treatment in case of irritate bowels syndrome in women, which contains from 0.002 to 0.02 mg of ramosetron hydrochloride as daily dose or equivalent molar amount of ramosetron or its other pharmacologically acceptable salt as active ingredient.EFFECT: invention ensures more efficient treatment of diarrhea syndrome in case of irritate bowels syndrome in women.6 cl, 10 ex

edical product for calf diarrhea treatment // 2342122
FIELD: medicine; veterinary medicine.SUBSTANCE: medical product contains polyvinylpyrolidone, Furacilinum, glucose, Acidum ascorbinicum and sodium hypochlorite at the certain component proportion.EFFECT: reduction of diarrhea duration on 36% (to 2.8 days); calf safety at level of 95% and additional weight increase on 15-44% after treatment, reduction of medical products consumption.2 tbl, 2 ex

Combinations containing antidiarrheal agent and epothylon or epothylon derivatives // 2330661
FIELD: medicine; pharmacology.SUBSTANCE: invention concerns a combination for proliferative disease treatment which contains antidiarrheal agent and epothylon derivative of formula (1) or epothylon derivative, method of diarrhoeia management, associated with epothylon introduction of formula (1), pharmaceutical composition, trade packing and medical product, including antidiarrheal agent and epothylon derivative.EFFECT: compositions have improved efficiency.9 cl, 6 ex

Antagonists of adenosine a2b receptors, pharmaceutical composition based on thereof and method for their preparing // 2318824
FIELD: organic chemistry, medicine, pharmacy.SUBSTANCE: invention relates to antagonists of adenosine A2B receptors and their using in treatment of mammals in different pathological states, such as digestive, immunological, neurological disorders and cardiovascular diseases caused both hyper-proliferation of cells and their apoptosis and similar disorders. Also, invention relates to methods for synthesis of these compounds and pharmaceutical composition containing thereof. The aim of the present invention is use of compounds of the general formulae (I) and (II) for preparing pharmaceutical composition possessing antagonistic activity with respect to adenosine A2B receptors wherein radical values are given in the invention description.EFFECT: valuable medicinal properties of compounds and pharmaceutical composition.41 cl, 12 sch, 35 ex
eans for treating irritated intestine syndrome cases with diarrhea predominance // 2314808
FIELD: medicine.SUBSTANCE: means has 0.001-0.05 mg of Ramozetron Hydrochloride as daily dose or equivalent molar quantity of Ramozetron or its other pharmaceutically permissible salt as active ingredient.EFFECT: enhanced effectiveness of treatment.12 cl
Pharmaceutical composition with anti-diarrhea effect // 2276979
FIELD: medicine, pharmacy.SUBSTANCE: invention relates to pharmaceutical compositions with anti-diarrheic effect. Pharmaceutical composition comprises the therapeutically effective amount of loperamide hydrochloride as an active component and special additives. Lactose, starch, aerosil, talk and stearate are used as special additives. Pharmaceutical composition is prepared in the form of solid gelatinous capsules. Loperamide capsules satisfy all requirement of the State Pharmacopoeia of XI Edition. Invention provides bioavailability of the pharmaceutical composition of loperamide capsules at the level 98.5%.EFFECT: improved and valuable pharmaceutical properties of composition.3 cl, 1 tbl, 3 ex
Preparation for treating diarrhea in youngsters of farm animals and method for its application // 2268040
FIELD: veterinary science.SUBSTANCE: the suggested preparation for treating diarrhea in farm animals youngsters contains bismuth salt in the form of bismuth-potassium ammonium citrate and, additionally, polyethylenoxide, moreover, preferably, it contains 1.5-2.5%-polyethylenoxide solution and 1.5-2.5%-bismuth-potassium ammonium citrate solution. The method for treating diarrhea deals with introducing the above-mentioned preparation once or twice daily for 1-2 d at the dosage of 1-75 ml/kg body weight. In young foxes it should be introduced at the dosage of 60-75 ml/kg body weight, in calves - at the dosage of 1-3 ml/kg body weight, in lambs - at the dosage of 2-3 ml/kg body weight. Application of the present complex preparation and therapeutic method enables to shorten terms of therapy by 1.5-2 times, decreases expenses for therapy by 3-5 times and provides decreased toxicological impact the preparation upon animal body.EFFECT: higher efficiency of therapy.6 cl, 3 ex, 2 tbl

Oral dosage forms with prolonged action // 2240786
The invention relates to pharmaceutical

Guanidinium heterocyclic compounds useful as agonists alpha-2 adrenergic receptors // 2194700
The invention relates to new guanidinium heterocyclic compounds of the formula (I), where R1denotes H, alkyl or is absent when R1missing link (a) is a double bond, D represents CR2, R2selected from H, alkyl, halogen, or, when is a CR3D can be N, denotes NR9, CR3=CR8, CR3, S, where R9denotes H, alkyl, alkenyl or quinil and where R3and R8selected from H, alkyl, alkenyl, quinil or cyano, R4, R5, R6each independently selected from H, alkyl, alkenyl, quinil, cyano, halogen or NH-C(= NR10)OTHER11(guanidine), R10and R11selected from H, methyl and ethyl, and where only one of R1, R5and R6is guanidines, R7selected from H, alkyl, alkenyl, quinil and halogen
Pharmaceutical composition having anti-diarrhoeal action // 2172172
The invention relates to medicine, specifically to medicines antidiarrheal action

The compound 7-(2-imidazolidinone) quinoline, suitable as agonists alpha-2-adrenergic receptors // 2161967
The invention relates to the field of organic chemistry and medicine and relates to new quinoline derivatives of General formula I, where R represents unsubstituted C1-C3-alkyl or C2-C3alkenyl; R1is cyano, which are agonists alpha-2-adrenergic receptors and can be used when obtaining drugs suitable for the treatment of nasal congestion, glaucoma, diarrhea, asthma

The method of modeling constipation // 2143911
The invention relates to medicine, specifically to experimental physiology, pharmacology and pathophysiology related to the possibility of modeling violations of motor-evacuation function of the intestines - constipation
 
2551367.
Up!